Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
- Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
- Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
- Associated Therapies
- Chemoradiotherapy, Radiation Therapy
Realizing Effectiveness Across Continents With Hydroxyurea (REACH)
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 635
- Registration Number
- NCT01966731
- Locations
- 🇦🇴
Hospital Pediátrico David Bernardino, Luanda, Angola
🇨🇩Centre Hospitalier Monkole, Kinshasa, Congo, The Democratic Republic of the
🇰🇪KEMRI/Wellcome Trust Research, Kilifi, Kenya
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
- Conditions
- Interventions
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 100
- Registration Number
- NCT01962415
- Locations
- 🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
- Conditions
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Target Recruit Count
- 257
- Registration Number
- NCT01949805
- Locations
- 🇧🇬
Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria
🇩🇪University Hospital Bonn, Center for Internal Medicine, Medical Clinic and Outpatient Clinic III, Bonn, Germany
🇵🇱Independent Public Teaching Hospital No.1 in Lublin, Lublin, Poland
Hydroxyurea in Pulmonary Arterial Hypertension
- Conditions
Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Prolong Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01848925
- Locations
- 🇨🇴
Fundacion BIOS, Barranquilla, Colombia
🇨🇴Hospital Pablo TobinUribe, Medellin, Colombia
🇵🇦PAMRI, Panama City, Panama
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
- Conditions
- Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Verrucous Carcinoma of the Oral CavityTongue CancerRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Verrucous Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the HypopharynxSalivary Gland Squamous Cell CarcinomaRecurrent Squamous Cell Carcinoma of the Larynx
- Interventions
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 48
- Registration Number
- NCT01847326
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Sickle Cell Disease - Stroke Prevention in Nigeria Trial
- Conditions
- Interventions
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT01801423
- Locations
- 🇳🇬
Aminu Kano Teaching Hospital, Kano, Nigeria
Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2020-08-20
- Target Recruit Count
- 150
- Registration Number
- NCT01783990
- Locations
- 🇺🇸
Sinai Hospital of Baltimore Alfred I Coplan Pediatric Hematology Oncology Outpatient Center, Baltimore, Maryland, United States
🇺🇸University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT01711541
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer
- Conditions
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 44
- Registration Number
- NCT01693718
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.